Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections
Sponsor: Centre Hospitalier Universitaire de Nice
Summary
Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis. One recent work from the Lyon (France) bone and joint infections reference center with data focusing mainly on hip and knee PJI has reported that C. acnes is the leading cause of late-onset PJI after coagulase negative staphylococci (CNS) (late acute PJI not considered). In such late-onset device-related infection, biofilm, as produced by C. acnes during PJI represents a major hurdle on the path to patient's cure. Because biofilm-associated bacteria have a slower metabolism and a lower multiplication rate than planktonic bacteria, antibiotic susceptibility can be hampered. Rifampicin is an antibiotic with low minimal bactericidal concentration against S. aureus and CNS biofilm-associated bacteria8 which significantly influence patient's outcome during staphylococci PJI.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
235
Start Date
2024-03-30
Completion Date
2027-07-01
Last Updated
2024-03-13
Healthy Volunteers
No
Conditions
Interventions
amoxicillin or moxifloxacin
Antibiotic treatment back bone during 12 weeks
amoxicillin or moxifloxacin + rifampicin
Antibiotic treatment back bone during 12 weeks + rifampicin
Locations (12)
CH Annecy Genevois
Annecy, France
CHU de BORDEAUX
Bordeaux, France
HCL
Lyon, France
AP-HM
Marseille, France
CHU de MONTPELLIER
Montpellier, France
CHU de Nantes
Nantes, France
CHU de NICE
Nice, France
Dianonesses croix saint simon
Paris, France
CHU de Rennes
Rennes, France
CHU Toulouse
Toulouse, France
Ch Tourcoing
Tourcoing, France
CHRU Tours
Tours, France